medigraphic.com
A partir del año 2010, la Revista Oficial del INER cambió a NCT (Neumología y Cirugía de Tórax)

 Ver actualización

2006, Number 4

<< Back Next >>

Rev Inst Nal Enf Resp Mex 2006; 19 (4)

Response to antituberculous therapy in patients previously treated for TB at the National Institute for Respiratory Diseases Ismael Cosío Villegas

Martínez D, Salazar LMA, Castillejos LMJ, García SFMC

Language: Spanish
References: 23
Page: 258-265
PDF size: 89.28 Kb.


ABSTRACT

Background: he National Institute of Respiratory Diseases Ismael Cosío Villegas (INER) is a national third level referral center for all respiratory diseases, including multitreaded pulmonary tuberculosis patients (PTb). The purpose of this study was to evaluate the results of supervised PTb retreatment at the INER in patients previously treated for PTb.
Methods: Retrospective review of clinical charts by a standardized questionary of previous treated PTb patients and whose new treatment was given and supervised al the INER from1994 to 2001. The response was analyzed according to the number of previous treatments, history of failure to previous treatments and presence or absence of MDR PTb.
Results: One hundred and forty seven patients had previously received treatment for PTb. The cure rates for patients with one, two, three or more previous PTb treatments were 68.2%, 40.4%, and 8.8% (p = 0.009); desertion 6.8%, 4.3%, and 3.1% (p = 0.7); failure 18.2%, 27.7%, and 25 % (p = 0.6) for each one of the groups, respectively. The proportion of MDR- PTb was 64.4%, 86.3%, and 94.4% in each group (χ2 trend, p = 0.0004). A previous treatment failure was a predictor of failure of treatment at the INER [OR = 2.4 (CI95% 0.9-9.64), p = 0.04]. According to resistance, cure rates were 71.4% for one drug resistance, MDR 44.9% and poly resistance 30.8% (χ2 trend, p= -03).
Conclusions: For patients with one or more failed previous treatments for PTb, receiving a new supervised treatment regime at the INER, there were low cure rates, a high proportion of treatment failures and a high rate of MDR-PTb.


REFERENCES

  1. Caminero JA. Management of multidrug-resistant tuberculosis and patients in retreatment. Eur Respir J 2005;25:928-936.

  2. Garcia-Garcia ML, Ponce de Leon A, Jimenez-Corona ME, et al. Clinical consequences and transmissibility of drug-resistant tuberculosis in Southern Mexico. Arch Intern Med 2000;160:630-636.

  3. Kwonjune JS, Irina EG, Gennadiy GP, et al. The effect of initial drug resistance on treatment response and acquired drug resistance during standardized short-course chemotherapy for tuberculosis. CID 2004;39: 1321-1328.

  4. Quy HT, Lan NT, Borgdorff MW, et al. Drug resistance among failure and relapse cases of tuberculosis: is the standard re-treatment regimen adequate? Int J Tuberc Lung Dis 2003;7:631-636.

  5. Secretaría de Salud. Guías para la atención de pacientes con tuberculosis multifarmacorresistente. México: Secretaría de Salud; 2004 (ISBN: 970-721-175-X).

  6. Villalba-Caloca J. ¿Por qué no se ha controlado la tuberculosis en México? Visión del Instituto Nacional de Enfermedades Respiratorias. Gac Med Mex 2003; 139:490-492.

  7. Migliori GB, Espinal M, Danilova ID, Punga VV, Grzemska M, Raviglione MC. Frequency of recurrence among MDR-TB cases “successfully” treated with standardized short-course chemotherapy. Int J Tuberc Lung Dis 2002;6:858-864.

  8. World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO report 2003. Geneva, World Health Organization, 2003 (WHO/CDC/TB/2003.316).

  9. World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO report 2004. Geneva, World Health Organization, 2004 (WHO/HTM/TB/2004.331).

  10. World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO report 2005. Geneva, World Health Organization, 2005 (WHO/HTM/TB/2005.349).

  11. World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO report 2006. Geneva, World Health Organization, 2006 (WHO/HTM/TB/2006.362).

  12. Secretaría de Salud. Norma Oficial Mexicana NOM-006-SSA2 1993. Para la prevención y control de la tuberculosis en la atención primaria a la salud. Diario Oficial de la Federación. México. Secretaría de Salud 1995; enero 26: 20-29.

  13. Secretaría de Salud. Modificación a la Norma Oficial Mexicana NOM-006-SSA2-1993. Para la prevención y control de la tuberculosis en la atención primaria a la salud. Diario Oficial de la Federación. Secretaría de Salud 2000; octubre 31.

  14. Kritski AL, Rodrigues LS, Andrade MK, et al. Retreatment tuberculosis cases. Factors associated with drug resistance and adverse outcomes. Chest 1997;111:1162-1167.

  15. Mendoza MT, Gonzaga AJ, Roa C, et al. Nature of drug resistance and predictors of multidrug-resistant tuberculosis among patients seen at the Philippine General Hospital, Manila, Philippines. Int J Tuberc Lung Dis 1997; 1:59-63.

  16. Perez-Guzman C, Vargas MH, Martinez-Rossier LA, Torres-Cruz A, Villarreal-Velarde H. Results of a 12-month regimen for drug-resistant pulmonary tuberculosis. Int J Tuberc Lung Dis 2002;6:1102-1109.

  17. Espinal MA, Laserson K, Camacho M, et al. Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int J Tuberc Lung Dis 2001; 5:887-893.

  18. DeRiemer K, Garcia-Garcia L, Bobadilla del Valle M, et al. Does DOTS work in populations with drug-resistant tuberculosis? Lancet 2005;365: 1239-1245.

  19. Becerra MC, Freeman J, Bayona J, et al. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2000;4: 108-114.

  20. Espinal MA, Kim SJ, Suarez PG, et al. Standard short-course chemotherapy for drug-resistant tuberculosis. Treatment outcomes in 6 countries. JAMA 2000; 283:2537-2545.

  21. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva, World Health Organization, 2006 (WHO/HTM/TB/2006.361).

  22. World Health Organization. Anti-tuberculosis drug resistance in the world. Third global report. The WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance, 1999–2002. Geneva, World Health Organization, 2004 (WHO/HTM/TB/2004.343).

  23. Salazar-Lezama MA, Torres-Cruz A, Valdez-Vazquez R, et al. Resultados de tratamiento de tuberculosis resistente en 91 pacientes del Instituto Nacional de Enfermedades Respiratorias: 2001-2003. Rev Inst Nal Enf Resp Mex 2004;17:15-21.




2020     |     www.medigraphic.com